Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Gastroenterology. 2018 May 24;155(3):740–751.e2. doi: 10.1053/j.gastro.2018.05.035

Figure 1.

Figure 1

Cumulative risk (hazard) for neoplastic progression (PDAC, IPMN-HGD, or PanIN-3) for high risk individuals after baseline screening. Overall neoplastic progression rate was 1.6% per year.